Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Abstract Background Tyrosine kinase inhibitors (TKIs) as first-line therapy for Chronic Myeloid Leukemia (CML) show a high success rate. However, a low number of patients with long-term treatment-free remission (TFR) were observed. Molecular relapse after imatinib discontinuation occurred at 50% at...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Aliza Mohd Yacob, Nor Asiah Muhamad, Kian Meng Chang, Hamidah Akmal Hisham, Yuslina Mat Yusoff, Latifah Ibrahim
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2022-03-01
Σειρά:	BMC Cancer
Θέματα:	Hsa-miR-181a-5p Hsa-miR-182-5p Hsa-miR-26a-5p Chronic myeloid leukemia Tyrosine kinase inhibitors Next generation sequencing
Διαθέσιμο Online:	https://doi.org/10.1186/s12885-022-09396-5
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!